Xponance Inc. Has $999,000 Stock Position in Repligen Co. (NASDAQ:RGEN)

Xponance Inc. boosted its holdings in shares of Repligen Co. (NASDAQ:RGEN) by 7.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 6,939 shares of the biotechnology company’s stock after buying an additional 459 shares during the quarter. Xponance Inc.’s holdings in Repligen were worth $999,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Ballentine Partners LLC increased its holdings in shares of Repligen by 4.0% during the 4th quarter. Ballentine Partners LLC now owns 1,879 shares of the biotechnology company’s stock worth $270,000 after acquiring an additional 72 shares during the last quarter. CIBC Asset Management Inc boosted its position in Repligen by 5.0% during the fourth quarter. CIBC Asset Management Inc now owns 1,706 shares of the biotechnology company’s stock worth $246,000 after purchasing an additional 81 shares during the period. MML Investors Services LLC increased its holdings in shares of Repligen by 2.7% in the third quarter. MML Investors Services LLC now owns 3,383 shares of the biotechnology company’s stock valued at $503,000 after purchasing an additional 89 shares during the last quarter. GAMMA Investing LLC raised its position in shares of Repligen by 15.2% in the fourth quarter. GAMMA Investing LLC now owns 684 shares of the biotechnology company’s stock valued at $98,000 after purchasing an additional 90 shares during the period. Finally, Louisiana State Employees Retirement System lifted its stake in shares of Repligen by 0.7% during the 4th quarter. Louisiana State Employees Retirement System now owns 14,500 shares of the biotechnology company’s stock worth $2,087,000 after buying an additional 100 shares during the last quarter. Institutional investors own 97.64% of the company’s stock.

Insider Buying and Selling at Repligen

In related news, Director Margaret Pax purchased 250 shares of the firm’s stock in a transaction that occurred on Monday, March 17th. The shares were bought at an average cost of $150.69 per share, with a total value of $37,672.50. Following the acquisition, the director now owns 1,043 shares of the company’s stock, valued at $157,169.67. This trade represents a 31.53 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Company insiders own 1.20% of the company’s stock.

Repligen Stock Performance

NASDAQ RGEN opened at $140.02 on Monday. The firm’s 50 day simple moving average is $156.18 and its 200 day simple moving average is $148.40. The firm has a market capitalization of $7.86 billion, a price-to-earnings ratio of -274.55, a P/E/G ratio of 4.54 and a beta of 0.95. The company has a current ratio of 10.44, a quick ratio of 8.76 and a debt-to-equity ratio of 0.26. Repligen Co. has a 1 year low of $113.50 and a 1 year high of $198.00.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings results on Thursday, February 20th. The biotechnology company reported $0.44 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.41 by $0.03. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%. The company had revenue of $167.55 million for the quarter, compared to analyst estimates of $167.58 million. As a group, research analysts expect that Repligen Co. will post 1.72 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

RGEN has been the topic of a number of research reports. Evercore ISI started coverage on shares of Repligen in a research note on Tuesday, March 18th. They issued an “in-line” rating and a $155.00 price target on the stock. StockNews.com lowered Repligen from a “hold” rating to a “sell” rating in a research note on Friday, February 21st. JPMorgan Chase & Co. boosted their price target on Repligen from $190.00 to $200.00 and gave the company an “overweight” rating in a research note on Friday, February 21st. Canaccord Genuity Group increased their price objective on Repligen from $165.00 to $170.00 and gave the stock a “hold” rating in a research report on Friday, February 21st. Finally, Royal Bank of Canada boosted their target price on shares of Repligen from $203.00 to $205.00 and gave the company an “outperform” rating in a research report on Friday, February 21st. One analyst has rated the stock with a sell rating, six have given a hold rating and eight have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $178.64.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.